Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. EIKN | 0.00 |
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:
EIKN) with a Underperform and lowers the price target from $7 to $5.
